Clinical Trials of Hypnotics
Karl Rickels
Abstract
Karl Rickels
Abstract
This article reviews the clinical literature of flurazepam, temazepam, and triazolam. The long half-life drug flurazepam and the short half-life drug triazolam produced similar results in terms of clinical improvement and adverse effects when equivalent dosages were administered. Temazepam, in the present U.S. formulation, appeared to be less effective in sleep latency than the other two compounds.
OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This article reviews the clinical literature of flurazepam, temazepam, and triazolam. The long half-life drug flurazepam and the short half-life drug triazolam produced similar results in terms of clinical improvement and adverse effects when equivalent dosages were administered. Temazepam, in the present U.S. formulation, appeared to be less effective in sleep latency than the other two compounds.
Key concepts: Flurazepam, Temazepam, Triazolam, Medicine, Dose, Clinical trial, Drug, Anesthesia